Mycenax Biotech Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 218.05 million compared to TWD 151.6 million a year ago. Net loss was TWD 167.39 million compared to TWD 116.43 million a year ago. Basic loss per share from continuing operations was TWD 0.82 compared to TWD 0.76 a year ago. Diluted loss per share from continuing operations was TWD 0.82 compared to TWD 0.76 a year ago.
For the six months, sales was TWD 356.44 million compared to TWD 377.15 million a year ago. Net loss was TWD 408.36 million compared to TWD 98.12 million a year ago. Basic loss per share from continuing operations was TWD 1.99 compared to TWD 0.64 a year ago. Diluted loss per share from continuing operations was TWD 1.99 compared to TWD 0.64 a year ago.